Search Results 121-130 of 17346 for Teratogenic

1. Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin - Mayo Clinic

   ... teratogenic;; Patients must be able to swallow whole tablets. Exclusion Criteria: Definitive clinical or radiologic evidence of distant (beyond cervical ...

2. CNS Tumors With Latent Residual Disease To Guide Individualized Therapies - Mayo Clinic

   Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects: Pregnant persons. Nursing persons.

3. A Study to Evaluate TVB-2640 and Trastuzumab Plus Paclitaxel or Endocrine Therapy for Treating Patients with HER2 Positive Advanced Breast Cancer - Mayo Clinic

   Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn ...

4. Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma - Mayo Clinic

   An agent that has known genotoxic, mutagenic and teratogenic effects: Pregnant persons;; Nursing persons;; Persons of childbearing potential who are unwilling ...

5. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma - Mayo Clinic

   However, IMiDs are known to be teratogenic. FCBP must have a negative serum ... teratogen. Because there is an unknown but potential risk for adverse ...

6. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma - Mayo Clinic

   Pregnant women are excluded from this study because olaparib is a PARP inhibitor with the potential for teratogenic or abortifacient effects. Because there ...

7. Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer - Mayo Clinic

   ... teratogenic. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date information regarding ...

8. LS1681: A Study of AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Participation eligibility · Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the ...

9. Lurbinectedin + Doxorubicin In Leiomyosarcoma - Mayo Clinic

   For this reason and because anti-cancer agents are known to be teratogenic ... Pregnant women are excluded from this study because lurbinectedin and doxorubicin ...

10. Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer - Mayo Clinic

    Radiation therapy ≤2 weeks prior to randomization. Any of the following, because this study involves agents whose genotoxic, mutagenic and teratogenic effects ...